NCT01980810

First Line Chemotherapy for Advanced Cancer

Pase 2 Study of Albumin-bounded Paclitaxel Plus S-1 as First-line Chemotherapy for Locally Advanced or Metastatic Gastric or Gastro-esophageal Adenocarcinoma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Chinese Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether albumine-bounded paclitaxel plus S-1 are effective in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma.

Detailed description

This phase II study was designed to evaluate the efficacy and safety of albumin-bounded paclitaxel combined with S-1 as first-line chemotherapy for inoperable and /or metastatic gastric or gastroesophageal junction cancer.Primary endpoint was overall response rate.

Conditions

• Gastric Cancer

Interventions

Type	Name	Description
DRUG	albumin-bounded paclitaxel	200mg iv d1, repeat every 2 weeks,until disease progression,or up to 9 cycles
DRUG	S-1	40mg/m2 po, bid,d1-10,repeated every 2 weeks until disease progression

Timeline

• Start date: 2013-09-01
• Primary completion: 2015-02-01
• Completion: 2016-02-01
• First posted: 2013-11-11
• Last updated: 2016-06-14

Locations

1 site across 1 country: China